POZ April-May 2016
POZ April-May 2016
In every issue, you’ll find the hottest topics of interest to our readers along with cutting-edge health information.
Also Available On:
Features
After Party: Why Does Crystal Meth Still Attract Gay Men?
Why does crystal meth still attract gay men?
Out of the Blue: Depression Is Often a Silent Partner to HIV
Depression is often a silent partner to HIV.
From the Editor
Higher Love
Depression is often a silent partner to HIV. For most of us living with the virus, depression shows up after we test positive.
Feedback
Letters-April/May 2016
Feedback on the loss of pets, Black Lives Matter, and dating and disclosure
POZ Q+A
Taking Action: Exploring the AIDS Action Committee
The AIDS Action Committee takes the lead in writing a blueprint to end the epidemic in Massachusetts.
POZ Planet
Online Injectors
A syringe exchange program with the CORNER Project in NYC meets today’s younger drug users where they hang out.
This Activist Wants to Take on Bill Maher
AIDS activist Maria Mejia was so outraged by HBO’s Real Time With Bill Maher, she started a Change.org petition.
HBO Looks at Mapplethorpe
This April, you can see the man behind the camera and the controversy when HBO airs Mapplethorpe: Look at the Pictures.
Liz Taylor’s Grand Legacy
In March, The Elizabeth Taylor AIDS Foundation presented the annual AIDSWatch in Washington, DC.
A (RED) Decade
This year marks the 10th anniversary of the (RED) organization, founded by rock star Bono and Bobby Shriver.
Spreading the Word on PrEP
A roundup of new promotions for pre-exposure prophylaxis (PrEP).
Voices
My Meth Weekend
POZ blogger Daniel Pintauro received the 2016 New Generation Arts & Activism Award from the Desert AIDS Project in Palm Springs, California.
Finding Hope
In a post titled “Losing Hope,” POZ blogger Aundaray Guess reflects on the unconditional love from his two dogs, Hope and Parker.
POZ Survey Says
Are You Prepared?
Everyone should make a plan for what to do in case of an emergency, but it’s especially important for people who are living with HIV.
Care and Treatment
FDA OKs Merck’s Hep C Treatment
The U.S. Food and Drug Administration (FDA) has approved Merck’s once-daily fixed-dose combination tablet Zepatier (grazoprevir/elbasvir)
ViiV Buys BMS Pipeline Drugs
ViiV Healthcare recently acquired Bristol-Myers Squibb’s (BMS) portfolio of HIV antiretrovirals (ARVs) in the pipeline.
HIV and Lung Cancer Risk
Much of the raised risk of lung cancer among the HIV population can be explained by individuals’ history with AIDS-related pneumonia.
Low Vitamin D May slow CD4 Recovery
Having low vitamin D may compromise immune recovery among people with HIV after they start antiretroviral (ARV) treatment.
Test and Treat, Plus PrEP Could Slash New HIV Cases
Screening for HIV and treating those who test positive, as well as providing Truvada as PrEP could greatly reduce new infections among MSM,
Research Notes
Prevention: A Slowing Epidemic
The U.S. HIV diagnosis rate fell by 19 percent during the past decade (while HIV testing rates held steady or increased in key populations).
Treatment: Antibody Infusion
A single infusion of an HIV antibody called VRC01 suppresses the virus in people not taking antiretrovirals (ARVs).
Cure: Alcoholism Drug
The anti-alcoholism drug Antabuse (disulfiram) apparently prompts the activation of cells latently infected with HIV.
Concerns: Failing Sex Ed
American schools are largely failing to provide young people with comprehensive sexual education, according to a recent CDC report.
POZ Heroes
Making Voices Count
Allan Clear left Harm Reduction Coalition to become the New York State Health Department’s director of drug user health.
